Psoriatic Arthritis
‘Devil is in the details’ for choosing relevant targets, endpoints in RA, PsA
DESTIN, Fla. — Making sense of the myriad targets for the myriad disease domains in rheumatoid arthritis and psoriatic arthritis presents ongoing challenges for every rheumatologist, a presenter said here..
Depression, treatment order impact biologic therapy persistence in psoriatic arthritis
Biologic therapy persistence in psoriatic arthritis often depends on whether the drug was a first or second treatment, with depression, anxiety, older age and higher tender joint count also leading to discontinuation, according to data.
IL-12/23, IL-23 inhibitors reduce risk for progression to inflammatory arthritis vs. TNFi
Patients with psoriasis treated with interleukin-12/23 or IL-23 inhibitors may be less likely to progress to inflammatory arthritis than those treated with TNF inhibitors, according to data published in The Lancet Rheumatology.
Izokibep demonstrates ‘marked improvements’ in psoriatic arthritis at 46 weeks
The interleukin-17 inhibitor izokibep has demonstrated positive safety and efficacy data at 46 weeks among patients with psoriatic arthritis, according to a press release from its manufacturer.
‘No evidence’ of increased short-term cancer risk for JAK inhibitors vs. TNF inhibitors
Clinical data found “no evidence” of a higher short-term cancer risk, except for non-melanoma skin cancer, in patients with rheumatoid arthritis or psoriatic arthritis starting Janus kinase inhibitors vs. TNF inhibitors, researchers wrote.
Female patients with psoriatic arthritis less likely to achieve therapy goals on bDMARDs
Female patients with psoriatic arthritis who receive biologic disease-modifying antirheumatic drugs are more likely to have more severe disease and less likely to reach low or minimal disease activity vs. male patients, according to data.
Glucocorticoid use, male sex predict more severe COVID-19 in psoriatic disease, axial SpA
Glucocorticoid use, older age, male sex and comorbidity burden are among the predictors of more severe COVID-19 in patients with psoriasis, psoriatic arthritis or axial spondyloarthritis, according to data.
Q&A: Exploring ‘challenging to treat’ areas of psoriasis
Healio spoke with Linda Stein Gold, MD, director of dermatology clinical research at Henry Ford Health, about the most difficult-to-treat body areas for psoriasis, treatment options, unmet needs in these cases and more.
Depression lowers pain threshold in psoriatic arthritis patients
Patients with psoriatic arthritis who suffer from depression may experience higher levels of pain despite having similar amounts of inflammation as those without depression.
Mandatory switching policies increased etanercept, infliximab biosimilar use in Canada
Mandatory switching policies for biosimilars are “much more” effective in increasing adoption than focusing on new start strategies, according to a study of Canadian health spending data published in Arthritis Care & Research.